Lilly's Partnering Priorities
At Lilly, we take smart risks on bold science to discover treatments and cures, all for one reason – patients. As a community of scientists, we recognize our responsibility as partners to help advance innovative medicines within our organization and beyond it. We understand that every partnership is unique – with distinctive aspects such as the stage, modality, therapeutic area, and culture. We have the necessary skills, capabilities, and know-how to bring a complete range of models to life and meet your specific needs. We approach every partnership with confidence, thoughtfulness, and enthusiasm. Together, we can make a difference in the lives of patients around the world.
Lilly is mainly looking for opportunities to work with external partners in the following scientific areas: Diabetes, Obesity and Cardiometabolic Diseases, Immunology, Neuroscience, Oncology, Adjacent Therapeutic Areas Indications, Emerging Technology and Platforms (including Genetic Medicines and Molecule Innovation), Health Tech, Diagnostics, Drug Delivery, R&D Tools, and Manufacturing, and Biotechnology Discovery Research.
Jake Van Naarden
Executive Vice President; President of Lilly Oncology and Head of Corporate Business Development
“At Lilly, partnerships are how bold science becomes real medicine. Our Corporate Business Development team is built to move fast, take smart risks, and find the right collaborators — wherever they are. We don’t wait for the science to come to us. We go find it, back it early, and bring the capabilities to help it go further. Because getting better treatments to patients faster isn’t just a goal — it’s the standard we hold ourselves to.”
Nisha Nanda
Group VP - Business Development, Head of Lilly Catalyze360
“The most consequential partnerships in science aren’t found — they’re built. At Lilly, we created Catalyze360 to do exactly that: to bring substantive resources and expertise to innovators at the earliest and most critical stages, and to engage with the breadth of the ecosystem in a way that a traditional pharma model simply can’t. Partnering isn’t a function for us. It’s how we think about what’s possible. The best ideas don’t wait for an invitation, and neither do we.”
Log in to BIO Partnering™ to send us a meeting request.
Corporate Business Development
Jake Shuman
VP - Global Head of Transactions and M&A
Wanda Rutledge-Gordon
VP - Global Head of Alliance and Innovation Management
Catalyze360
Aliza Apple
VP – Global Head of Lilly TuneLab and Catalyze360 AI/ML
Tom Hopkins
VP - Global Head of Lilly ExploR&D
Kathleen Lin
Sr. Director & Site Head of Lilly Gateway Labs San Diego
Search & Evaluation
Benjamin Yaden
VP - Global Head of Cardiometabolic Research, Women’s Health & Healthy Aging, Search & Evaluation
David Shrom
VP - Global Head Immunology Search & Evaluation
Jenny Laird
VP - Global Head Neuroscience Search & Evaluation
Andrew Korytko
VP - Molecule Innovation (Biologics) Search & Evaluation
Lilly Ventures
Jim MacKrell
VP - Global Head of Lilly Venture Science
Tim Luker
VP - Venture Science - West Coast
Zhaoying Xu
Executive Director, Lilly Ventures China
Lilly Ventures
Rebecca Canter
Executive Director - Venture Sciences, Europe
Gurkeerat Singh
Associate VP-Venture Capital – Japan/Asia, Venture Science.
